Wu GH - Search Results

1

Achieving hepatitis C elimination in Taiwan-Overcoming barriers by setting feasible strategies.

Wu GH, Pwu RF, Chen SC. Wu GH, et al. J Formos Med Assoc. 2018 Dec;117(12):1044-1045. doi: 10.1016/j.jfma.2018.10.021. Epub 2018 Nov 16. J Formos Med Assoc. 2018. PMID: 30449458 Free article. No abstract available.

2

Taiwan is on track of accelerating hepatitis C elimination by 2025.

Wu GH, Pwu RF, Chen SC, Chen DS. Wu GH, et al. Liver Int. 2020 Jun;40(6):1506-1507. doi: 10.1111/liv.14412. Epub 2020 Mar 8. Liver Int. 2020. PMID: 32086990 No abstract available.

3

The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study.

Wu GH, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS, Lu SN. Wu GH, et al. J Formos Med Assoc. 2021 Jul;120(7):1444-1451. doi: 10.1016/j.jfma.2021.01.005. Epub 2021 Jan 27. J Formos Med Assoc. 2021. PMID: 33516585 Free article.

4

Taiwan accelerates its efforts to eliminate hepatitis C.

Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Chien RN, et al. Among authors: wu gh. Glob Health Med. 2021 Oct 31;3(5):293-300. doi: 10.35772/ghm.2021.01064. Glob Health Med. 2021. PMID: 34782872 Free PMC article. Review.

5

The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.

Yang WW, Juan YC, Wu GH, Pwu RF. Yang WW, et al. Among authors: wu gh. Drug Saf. 2024 Apr;47(4):289-299. doi: 10.1007/s40264-023-01386-1. Epub 2023 Dec 19. Drug Saf. 2024. PMID: 38113017

6

The Development of Health Technology Assessment in Taiwan: Perspectives and Analysis.

Pwu RF, Cheng YS, Yang WW, Wu GH. Pwu RF, et al. Among authors: wu gh. Health Syst Reform. 2023 Dec 31;9(3):2330396. doi: 10.1080/23288604.2024.2330396. Epub 2024 May 7. Health Syst Reform. 2023. PMID: 38715195

7

Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.

Liou WS, Hsieh SC, Chang WY, Wu GH, Huang HS, Lee C. Liou WS, et al. Among authors: wu gh. Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):752-9. doi: 10.1002/pds.3445. Epub 2013 Apr 29. Pharmacoepidemiol Drug Saf. 2013. PMID: 23625864

8

The role of FERMT2 in the tumor microenvironment and immunotherapy in pan-cancer using comprehensive single-cell and bulk sequencing.

Wu GH, He C, Che G, Zhou Z, Chen BY, Wu HM, Chen JF, Zhu WP, Yang Y, Zhou Z, Teng LS, Wang HY. Wu GH, et al. Heliyon. 2024 May 1;10(9):e30505. doi: 10.1016/j.heliyon.2024.e30505. eCollection 2024 May 15. Heliyon. 2024. PMID: 38726194 Free PMC article.

9

[The development and innovation of clinical nutrition].

Wu GH. Wu GH. Zhonghua Wai Ke Za Zhi. 2024 Apr 29;62(6):525-531. doi: 10.3760/cma.j.cn112139-20240228-00091. Online ahead of print. Zhonghua Wai Ke Za Zhi. 2024. PMID: 38682622 Chinese.

10

FoxO3 Regulates Mouse Bone Mesenchymal Stem Cell Fate and Bone-Fat Balance During Skeletal Aging.

Yu W, Tong MJ, Wu GH, Ma TL, Cai CD, Wang LP, Zhang YK, Gu JL, Yan ZQ. Yu W, et al. Among authors: wu gh. Stem Cells Dev. 2024 May 13. doi: 10.1089/scd.2024.0055. Online ahead of print. Stem Cells Dev. 2024. PMID: 38661524

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page